Biocept, Inc. (BIOC) Receives $2.50 Consensus Target Price from Brokerages
Shares of Biocept, Inc. (NASDAQ:BIOC) have earned an average rating of “Hold” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $2.50.
A number of equities analysts have recently commented on the company. Westpark Capital reissued an “outperform” rating on shares of Biocept in a report on Thursday, August 3rd. ValuEngine raised Biocept from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Finally, Zacks Investment Research cut Biocept from a “buy” rating to a “hold” rating in a report on Thursday, June 1st.
Several institutional investors have recently bought and sold shares of BIOC. Vanguard Group Inc. boosted its position in Biocept by 9.6% in the second quarter. Vanguard Group Inc. now owns 764,351 shares of the medical research company’s stock worth $1,048,000 after buying an additional 66,746 shares during the period. Intellectus Partners LLC boosted its position in Biocept by 6,250.0% in the first quarter. Intellectus Partners LLC now owns 127,000 shares of the medical research company’s stock worth $271,000 after buying an additional 125,000 shares during the period. WealthTrust Axiom LLC acquired a new position in Biocept during the first quarter worth approximately $298,000. Finally, Creative Planning boosted its position in Biocept by 64,679.8% in the second quarter. Creative Planning now owns 246,811 shares of the medical research company’s stock worth $338,000 after buying an additional 246,430 shares during the period. 6.92% of the stock is owned by institutional investors.
Biocept (BIOC) traded down 2.56% during midday trading on Wednesday, hitting $1.14. 150,244 shares of the company traded hands. The stock has a 50 day moving average price of $1.35 and a 200-day moving average price of $1.66. The company’s market cap is $34.49 million. Biocept has a 12-month low of $0.74 and a 12-month high of $3.39.
Biocept (NASDAQ:BIOC) last announced its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.01. The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. Analysts expect that Biocept will post ($0.79) EPS for the current year.
WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/28/biocept-inc-bioc-receives-2-50-consensus-target-price-from-brokerages.html.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Stock Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related stocks with our FREE daily email newsletter.